Skip navigation

  Cramer's six in 60: 'Horrible' IPO

FDA draft guidance on generic eye drug push Allergen shares lower

WASHINGTON (Reuters) - Shares of Allergan Inc <AGN.N> fell 12 percent on Monday after U.S. regulators issued draft guidance that would enable generic versions of the company's dry eye drug Restasis to come to market more quickly. Full story

Botox Boom or Bust?

  David Pyott, Allergan president and CEO discusses his company's 2012 outlook and the Botox market.

Allergan CEO on Botox Expansion

  Allergan filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladders. David Pyott, chairman & CEO of Allergan, offers insight on Botox and its many uses.

Sponsored Links

Articles

Botox-maker pays $600M to resolve investigation

Video

  Cramer's Six in 60 Stocks

CNBC's Jim Cramer gives his take on six stocks in 60 seconds, including Oracle, Allergan, Southwest Airlines and others.

advertisement | ad info

Related Photos

Pyott, CEO of Allergan, speaks during the Reuters Health Summit in New York
Pyott, CEO of Allergan, speaks during the Reuters Health Summit in New York

David Pyott, CEO of Allergan, speaks during the Reuters Health Summit in New York, May 9, 2011. REUTERS/Brendan McDermid